Professor Ronit Satchi-Fainaro is a Professor of Pharmacology in the Department of Physiology and Pharmacology at the Sackler Faculty of Medicine, Tel Aviv University. During my 13 years at Tel Aviv University, I gathered a multidisciplinary group of 30 outstanding scientists and a variety of collaborators in the pursuit of answering big questions such as: What triggers dormant cancers to switch to a fast-growing phenotype after long periods of time? What is the reason that some cancer cells choose one organ as opposed to another as a metastatic niche? Is there a certain sub-population of tumor cells within a tumor that holds a high angiogenic potential? Does it correlate with their ability to be “tumor initiating cells”?; and last but not least, based on the answers to these questions, can highly-selective drugs be designed to eradicate this sub-population of cells and by that- eliminate the tumors, fulfilling the “Magic Bullet” dream envisioned by Paul Ehrlich more than 100 years ago? To this end, we identified molecular signatures that predict tumor dormancy associated with incompetency to recruit the supporting stromal microenvironment and the factors determining long-term survivorship of cancer patients. Based on these signatures, my lab was the first to rationally-design multi-modality targeted nano-vaccines and polymer therapeutics combining synergistically anti-stromal agents with chemotherapeutics and RNAi that offer the potential for improved efficacy and diminished toxicity in the treatment of cancer by targeting both the immune system and the tumor tissue directly. My research focuses on tumor biology, cancer dormancy, tumor-host interactions, angiogenesis, molecular and non-invasive intravital imaging of animal models of cancer, 3D-printed cancer models and personalized nanomedicines for cancer theranostics (therapy and diagnostics). Throughout, I have maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. My multidisciplinary research laboratory focuses on basic research elucidating the mechanisms underlying the switch from dormancy leading to the discovery of new molecular targets interrupting tumor-host interactions. My laboratory has long-standing interest in polymer-based systems for drug delivery of small molecules, oligonucleotides and peptides for the treatment of cancer, and other angiogenesis-dependent diseases. Our approach is followed by the design of highly-selective targeting molecules integrating biology, chemistry, protein engineering, molecular imaging, computational approaches, material sciences and nanotechnology to selectively guide drugs and biological entities into pathological sites. I am leading multi-investigators, multi-institutional and multidisciplinary projects. I have organized several international symposiums including the 2019 Gordon Research Conference on Cancer Nanomedicine.